Agree with focussing on the data. As part of its review, the FiftyOne Capital report takes a look at the data from a study in 2005 (Ghosh). The most important takeaway for me is that the Ghosh study would have met the primary endpoints for our P2 trial, and we are providing twice the dosage of the that study!! The effect of this can be seen already in the SAS results that have been released (similar dosage to our P2) which are much better than the (already significant) Ghosh data. The 2005 paper is at this link and worth a read for data driven investors............
https://www.sciencedirect.com/science/article/pii/S0011393X05001311
Fifty One Capital updated report, page-52
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.055(20.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 33.5¢ | 27.5¢ | $1.328M | 4.323M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152597 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
